血小板ACKR3/CXCR7倾向于抗血小板脂质而非动脉粥样血栓性脂质组并调控血栓炎症
研究验证血小板ACKR3/CXCR7通过影响血小板脂质组调控血栓炎症反应。冠状动脉疾病患者血小板ACKR3/CXCR7表达增强且聚集减少,CXCR7激动剂VUF11207在体外显著降低急性冠脉综合征患者血小板的促血栓反应,在体内减少心肌梗死和动脉损伤后的血栓功能及血小板-白细胞相互作用,并促进抗血栓脂质DGLA和12-HETrE生成。
要点
- 冠状动脉疾病患者血小板ACKR3/CXCR7表达增强且聚集减少。
- CXCR7激动剂VUF11207体外降低急性冠脉综合征患者血小板促血栓反应。
- ACKR3/CXCR7激活促进抗血栓脂质DGLA和12-HETrE生成而非促血栓脂质。
核心结论
- ACKR3/CXCR7可能为急慢性血栓炎症加重的心血管病理和冠状动脉疾病提供新的治疗策略。
研究设计与样本
- 研究纳入冠状动脉疾病患者和健康受试者,进行体外血小板功能检测、靶向和非靶向脂质组学分析,并在体内评估CXCR7激动剂对心肌梗死和动脉损伤后血栓功能的影响。
主要发现
- 冠状动脉疾病患者血小板ACKR3/CXCR7表达增强且聚集减少。
- CXCR7激动剂VUF11207在体外显著降低急性冠脉综合征患者血液中的促血栓血小板反应。
- CXCR7激动剂在体内减少心肌梗死和动脉损伤后的血栓功能及血栓炎症性血小板-白细胞相互作用。
- ACKR3/CXCR7激活不影响表面受体可用性、凝血谱、出血时间、血浆依赖性凝血酶生成或血凝块形成,但抵消激活诱导的磷脂酰丝氨酸暴露和促凝血血小板辅助的凝血酶生成。
- ACKR3/CXCR7激活在健康受试者和冠状动脉疾病患者中促进抗血栓脂质DGLA和12-HETrE生成,而非COX-1或12-LOX代谢的促血栓脂质和磷脂酶衍生的致动脉粥样硬化脂质。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Platelet ACKR3/CXCR7 surface expression is enhanced and influences prognosis in coronary artery disease (CAD) patients, who exhibit a distinct atherothrombotic platelet lipidome. Current investigation validates the potential of ACKR3/CXCR7 in regulating thromboinflammatory response through its impact on the platelet lipidome. CAD patients with enhanced platelet ACKR3/CXCR7 expression exhibited reduced aggregation. Pharmacological CXCR7 agonist (VUF11207) significantly reduced prothrombotic platelet response in blood from acute coronary syndrome patients ex vivo. CXCR7 agonist administration reduced thrombotic functions and thromboinflammatory plateletleukocyte interactions post-myocardial infarction and arterial injury in vivo. ACKR3/CXCR7 ligation did not affect surface availability of surface receptors, coagulation profile, bleeding time, plasma-dependent thrombin generation (thrombinoscopy), or clot formation (thromboelastography) but counteracted activation-induced phosphatidylserine exposure and procoagulant platelet-assisted thrombin generation. Targeted (micro-UHPLC-ESI-QTrap-MS/MS) and untargeted (UHPLCESI-QTOF-MS/MS) lipidomics analysis revealed that ACKR3/CXCR7 ligation favored generation of antithrombotic lipids (dihomo-γ-linolenic acid [DGLA], 12-hydroxyeicosatrienoic acid [12-HETrE]) over cyclooxygenase-1 (COX-1) or 12-lipoxygenase (12-LOX) metabolized prothrombotic and phospholipase-derived atherogenic lipids in healthy subjects and CAD patients, contrary to antiplatelet therapy. Through 12-HETrE, ACKR3/CXCR7 ligation coordinated with Gαs-coupled prostacyclin receptor to trigger cyclic adenosine monophosphate/protein kinase A-mediated platelet inhibition. ACKR3/CXCR7 ligation reduced generation of lipid agonists and lipid signaling intermediates, which affected calcium mobilization, intracellular signaling, and consequently platelet interaction with physiological matrices and thromboinflammatory secretome. This emphasized its functional dichotomy from prothrombotic CXCR4. Moreover, CXCR7 agonist regulated heparin-induced thrombocytopenia-sera/immunoglobulin G-triggered platelet and neutrophil activation, heparin-induced platelet aggregation, generation of thromboinflammatory lipids, platelet-neutrophil aggregate formation, and thromboinflammatory secretion ex vivo. Therefore, ACKR3/CXCR7 may offer a novel therapeutic strategy in acute/chronic thromboinflammation exaggerated cardiovascular pathologies and CAD.
引用
- Cebo M, Dittrich K, Fu X, et al. Platelet ACKR3/CXCR7 favors antiplatelet lipids over an atherothrombotic lipidome and regulates thromboinflammation. Blood. 2022. PMID: 34905596. doi:10.1182/blood.2021013097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。